Tentarix Biotherapeutics

About Tentarix Biotherapeutics

Tentarix Biotherapeutics is focused on creating conditionally active multispecific biologics with a high therapeutic index to address unmet needs in complex therapeutic areas. Their mission is to redefine conditionally active biologics using proprietary platforms to develop highly differentiated therapies.

Products & Services

Conditionally Active Multispecific Biologics:Designed to reach difficult-to-treat targets with high therapeutic index, leveraging validated biology.

VH-Select™:A stabilized fully human VH scaffold for binder discovery, overcoming expression challenges and enabling potent biological activity.

FunctionSeq™:Combines mammalian display with NGS screening to identify conditional multispecifics, ensuring precise activation on targeted cells.

Specialties

Conditionally Active Biologics Oncology (including Immuno-Oncology) Autoimmune Disease Multispecific Biologics Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 35000000 MR: - FA: $35 million FAN: 35000000	D: 2023-09-06 FD: 2023-09-06	4 investors

Series B Latest

2023-09-06

$35.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Andy Kidd

Chief Executive Officer

S

Stephen Demarest

Chief Scientific Officer

M

Margaret Karow

Chief Development Officer

A

Ash Khanna

CHIEF BUSINESS OFFICER

B

Brady Johnson

Senior Vice President, Operations and Finance

D

Dallas Jones

Senior Vice President, Biology

View 17 more team members with Pro

Unlock Full Team Directory

Recent News